Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Voy is a medical weight-loss service targeting markets such as the UK, Germany, Brazil, and India, with the current page focusing on Voy India. It is not a standalone AI tool in the traditional sense, but a digital weight-loss platform built around GLP-1 medication-based treatment. It offers eligibility assessment, consultations with endocrinologists, personalized treatment plans, cold-chain medication delivery, lab testing, a smart scale, app-based tracking, and lifestyle coaching.
The page emphasizes “science-backed” and doctor-led care: users first complete a free online assessment, then consult with an endocrinologist, and if eligible, receive a GLP-1 treatment plan. Ongoing services include home delivery of medication, side-effect support, nutrition and exercise guidance, tracking of 14+ body metrics, full-body lab testing, and long-term treatment adjustments. Typical users include people with obesity or excess weight, as well as those dealing with metabolic health issues such as blood sugar concerns, high blood pressure, PCOS, or fatigue.
Although the domain is categorized under AI apps/tools, the scraped page does not clearly disclose any AI models, recommendation algorithms, or automated diagnostic/treatment capabilities. It only mentions that the app can track diet, vital signs, habits, and workouts, and provide instant chat, as well as that researchers work on predictive medicine and modeling research. This is not enough to conclude that the product has specific AI capabilities. In terms of output quality, Voy cites data such as a study with 57,975 participants, an average weight loss of 21%, and 53% more weight loss compared with medication alone. However, the page does not present the full study methodology, contraindications, or evidence on maintaining results after long-term discontinuation.
The page includes “View plans” and “Book your consult now,” but does not disclose pricing, medication costs, lab testing fees, or subscription periods. Clearly stated items include a free eligibility assessment, doctor follow-ups, coaching, the app, lab testing, a smart scale, and a “10% weight loss in 6 months or money back” commitment. Payment methods are not disclosed.
The main advantage is that the medical care pathway appears relatively complete, combining doctors, medication, testing, devices, and behavioral support into a closed loop. It is best suited for people who want to pursue long-term weight loss under professional supervision. The drawbacks are limited price transparency, the fact that GLP-1 is not suitable for everyone, and the page’s limited disclosure around privacy, compliance, AI capabilities, and risks.
Availability for mainland China users in terms of access, payment, and medication delivery is unknown. Even if the website is accessible, cross-border prescription medication, cold-chain delivery, and doctor licensing are generally difficult to apply directly to users in China. More practical alternatives for Chinese users would be endocrinology or obesity clinics at local top-tier hospitals, or compliant weight-management services offered by licensed internet hospitals in China.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on early.fit official site.
early.fit is an India AI Apps provider. TG4G tracks its product information, an overall rating of 5.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach early.fit directly.